INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 412m ago
HOUSE PTR12m ago
SEC 13F12m ago
ROBINHOOD CHAIN11m ago
SEC FORM 4/Option exerciseVerified dataRule 10b5-1 plan

Quigley Jill M. reported TERN

Director · Terns Pharmaceuticals, Inc. · Common Stock

Side
M
Value
$227K
Shares
24.5K
Price
$9.24
Executed
Nov 4, 2025
Disclosed
Nov 5, 2025
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Nov 4 executedNov 5, 2025 disclosed

TERN · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
2/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+4 / 25

$227K reported value · new position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · TERN

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    11
    BL
    Burroughs Amy L.Director, Chief Executive Officer
    TERNTerns Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$282K
    7,521 sh
    		Jan 15, 2026Jan 16, 2026
    traded Jan 15, 2026
    		+1dSEC FORM 4

    Evidence

    0
    BL
    Burroughs Amy L.Director, Chief Executive Officer
    TERNTerns Pharmaceuticals, Inc.
    Option exercise · 10b5-1 plan
    		M—
    27.1K sh
    		Jan 15, 2026Jan 16, 2026
    traded Jan 15, 2026
    		+1dSEC FORM 4

    Evidence

    0
    BL
    Burroughs Amy L.Director, Chief Executive Officer
    TERNTerns Pharmaceuticals, Inc.
    Option exercise · 10b5-1 plan
    		M—
    14.6K sh
    		Jan 15, 2026Jan 16, 2026
    traded Jan 15, 2026
    		+1dSEC FORM 4

    Evidence

    21
    KE
    Kuriakose EmilChief Medical Officer
    TERNTerns Pharmaceuticals, Inc.
    Grant or award
    		A—
    56.3K sh
    		Jan 14, 2026Jan 16, 2026
    traded Jan 14, 2026
    		+2dSEC FORM 4

    Evidence

    9
    KE
    Kuriakose EmilChief Medical Officer
    TERNTerns Pharmaceuticals, Inc.
    Grant or award
    		A—
    112.5K sh
    		Jan 14, 2026Jan 16, 2026
    traded Jan 14, 2026
    		+2dSEC FORM 4

    Evidence

    11
    BL
    Burroughs Amy L.Director, Chief Executive Officer
    TERNTerns Pharmaceuticals, Inc.
    Grant or award · 10b5-1 plan
    		A—
    150.0K sh
    		Jan 14, 2026Jan 16, 2026
    traded Jan 14, 2026
    		+2dSEC FORM 4

    Evidence

    6
    BL
    Burroughs Amy L.Director, Chief Executive Officer
    TERNTerns Pharmaceuticals, Inc.
    Option exercise · 10b5-1 plan
    		M$126K
    27.1K sh
    		Jan 15, 2026Jan 16, 2026
    traded Jan 15, 2026
    		+1dSEC FORM 4

    Evidence

    6
    BL
    Burroughs Amy L.Director, Chief Executive Officer
    TERNTerns Pharmaceuticals, Inc.
    Option exercise · 10b5-1 plan
    		M$126K
    27.1K sh
    		Jan 15, 2026Jan 16, 2026
    traded Jan 15, 2026
    		+1dSEC FORM 4

    Evidence

    2
    BL
    Burroughs Amy L.Director, Chief Executive Officer
    TERNTerns Pharmaceuticals, Inc.
    Option exercise · 10b5-1 plan
    		M$68K
    14.6K sh
    		Jan 15, 2026Jan 16, 2026
    traded Jan 15, 2026
    		+1dSEC FORM 4

    Evidence

    18
    BL
    Burroughs Amy L.Director, Chief Executive Officer
    TERNTerns Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$2.27M
    61.2K sh
    		Jan 15, 2026Jan 16, 2026
    traded Jan 15, 2026
    		+1dSEC FORM 4

    Evidence

    0
    BL
    Burroughs Amy L.Director, Chief Executive Officer
    TERNTerns Pharmaceuticals, Inc.
    Grant or award · 10b5-1 plan
    		A—
    300.0K sh
    		Jan 14, 2026Jan 16, 2026
    traded Jan 14, 2026
    		+2dSEC FORM 4

    Evidence

    0
    BL
    Burroughs Amy L.Director, Chief Executive Officer
    TERNTerns Pharmaceuticals, Inc.
    Option exercise · 10b5-1 plan
    		M—
    27.1K sh
    		Jan 15, 2026Jan 16, 2026
    traded Jan 15, 2026
    		+1dSEC FORM 4

    Evidence

    0
    QM
    Quigley Jill M.Director
    TERNTerns Pharmaceuticals, Inc.
    Option exercise · 10b5-1 plan
    		M—
    24.5K sh
    		Nov 4, 2025Nov 5, 2025
    traded Nov 4, 2025
    		+1dSEC FORM 4

    Evidence

    23
    QM
    Quigley Jill M.Director
    TERNTerns Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$441K
    24.5K sh
    		Nov 4, 2025Nov 5, 2025
    traded Nov 4, 2025
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001799780-25-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 4, 2025
    Published
    Nov 5, 2025
    Ingested by INSIDER
    Nov 5, 04:34 UTC
    Last re-read
    Nov 5, 04:34 UTC

    Extracted facts

    Filer
    Quigley Jill M.
    Role
    Director
    Transaction
    Option exerciseAs filed: “M”
    Asset
    Terns Pharmaceuticals, Inc.
    Ticker
    TERN
    Shares
    24.5K
    Price per share
    $9.24
    Value
    $226,565
    Execution date (reported)
    Nov 4, 2025
    Owned after transaction
    24.5K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    1

    Calculation

    Value = shares × reported price per share

    • Shares: 24.5K
    • Price: $9.24

    = $226,565

    What this establishes

    Quigley Jill M. filed this Form 4 reporting a option exercise of TERN on Nov 4, 2025. It became public on Nov 5, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Quigley Jill M.cik:0001799780
    Issuer
    Terns Pharmaceuticals, Inc.cik:0001831363

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.

    Source error

    Price history for TERN is unavailable.

    An error occurred in the Server Components render. The specific message is omitted in production builds to avoid leaking sensitive details. A digest property is included on this error instance which may provide additional details about the nature of the error.